Grant Funding for Large Molecule Safety Testing
Contact Our Team
For more information about how Halldale can add value to your marketing and promotional campaigns or to discuss event exhibitor and sponsorship opportunities, contact our team to find out more
The Americas -
holly.foster@halldale.com
Rest of World -
jeremy@halldale.com
Simulations Plus’ DILIsym Services (DSS) division and the University of Pittsburgh Drug Discovery Institute (UPDDI) have jointly received a Phase I NIH-funded SBIR grant. The collaboration will combine DSS software (DILIsym) and UPDDI’s vLAMPS experimental liver model and the microphysiology systems database (MPS-Db). The system will be used to predict the safety of large (macro) molecules such as proteins that are increasingly used to treat diseases. The first phase of development funded by the grant will include beta version software construction and vLAMPS testing of several large molecules captured in the MPS-Db. Successful completion of the objectives will lead to an application for a larger Phase II grant, which would fully fund the development of the joint commercial offering.
What are some of the best reporting practices to encourage safety reporting? Find out in Safety Reporting in Safety Critical Industries.
DSS coordinates the DILI-sim Initiative, which is a public-private partnership that has guided development of the DILIsym software package. This software uses properties of drugs to predict their risk of causing liver injury in patients, and is now widely used to support key drug development decisions. To date, this approach has been successfully applied to traditional small molecule drugs. Similarly, the UPDDI has developed the vLAMPS and MPS-Db technologies for other drug development applications. The focus on large molecule safety in an integrated fashion represents a new direction for both organizations, allowing them to support development of safer large molecule therapeutics.
Dr. D. Lansing Taylor, Director of the UPDDI, Distinguished Professor and Allegheny Foundation Professor of Computational and Systems Biology, stated: “The integration of our biomimetic human liver MPS (vLAMPS) with the MPS-Db and DILIsym computational modeling is a powerful application of quantitative systems pharmacology to large molecule safety and will advance large molecule safety testing.”
